Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Gastric Cancer Clinical Trial

Official title:

A Phase 1b/2Study of Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss (MANTRA-4)

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT06090318
• Other study ID #: RAIN-3204
• Status: Withdrawn
• Phase: Phase 1/Phase 2
• Start date: May 19, 2023
• Est. completion date: May 30, 2023

Study information

• Verified date: October 2023
• Source: Rain Oncology Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, single-arm, Phase 1b/2 study designed to evaluate the safety, tolerability, and preliminary efficacy of milademetan in combination with atezolizumab in patients with advanced solid tumors with confirmed homozygous CDKN2A loss and WT TP53 who have progressed on or are refractory to prior PD-1/PD-L1 inhibitor therapy and who, in the opinion of the Investigator, are unlikely to tolerate or derive clinically meaningful benefit from other therapy. This study will determine the recommended dose of milademetan when given in combination with atezolizumab (the combination RP2D) using a dose de-escalation safety assessment cohort (Phase 1b). Following identification of the combination RP2D, the safety profile and preliminary anti-tumor activity of the combination RP2D will be evaluated in a larger population in a dose expansion cohort (Phase 2).

Description:

Up to 30 patients will be enrolled, 3 to 18 patients in the safety assessment cohort and 12 to 27 patients in the dose expansion cohort.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 30, 2023
• Est. primary completion date: May 30, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Has a histologically confirmed, advanced solid tumor that has progressed on prior therapy with an anti-PD-1/L1 inhibitor administered as either monotherapy or in combination with other therapies
• Has documented homozygous CDKN2A loss and Wild-Type TP53
• Confirmation of available tumor tissue collected within 5 years of enrollment
• Measurable tumor lesions per RECIST 1.1
• Estimate life expectancy of at least 6 months
• ECOG PS of 0 or 1
• Resolution of clinically relevant toxic effect of prior anti-cancer therapies Note:

AEs from prior therapy must resolve to Grade = 1 per the NCI CTCAE version 5.0, except for peripheral neuropathy, which must resolve to Grade = 2, and alopecia

• Adequate bone marrow, renal and hepatic function

Key Exclusion Criteria:

• Has received prior treatment with any MDM2 inhibitor; prior treatment with atezolizumab is allowed except if the patient discontinued due to toxicity
• Has a history of any Grade 3 or 4 immune-related toxicities to a prior checkpoint inhibitor treatment or history of treatment discontinuation with prior checkpoint inhibitor use due to toxicity
• Endocrinopathies which are stable with appropriate hormonal supplementation consistent with other eligibility parameters
• Dermatologic events which have resolved to Grade = 1 on stable medication, as appropriate, and consistent with other eligibility parameters
• Treatment with systemic immunosuppressive medication, including but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and antitumor necrosis factor agents, within 2 weeks prior to the first dose of study treatment or anticipation of need for systemic immunosuppressive medication during the course of the study
• Has an uncontrolled infection within the 7 days prior to Screening
• Has undergone treatment with therapeutic oral or IV antibiotics within 2 weeks prior to first dose of study treatment
• Has known active central nervous metastases and/or carcinomatous meningitis. Note:

Patients who require steroids for brain metastases must be on a stable or tapering dose of corticosteroids for at least 2 weeks before the first dose of study treatment. If applicable, patients must complete stereotactic radiosurgery 7 days before, and spinal or whole brain radiotherapy 21 days before, their first dose of study treatment

• Has as other primary malignancies that have required systemic antineoplastic treatment within 2 years prior to Screening, except for localized cancers that have apparently been cured (eg, nonmelanoma skin cancer, superficial bladder cancer, or carcinoma in situ of the prostate, cervix, or breast) and will not interfere with the study outcomes
• Has uncontrolled or significant cardiovascular disease

Related Conditions & MeSH terms

• Advanced Solid Tumor
• Carcinoma
• Carcinoma, Renal Cell
• Gastric Cancer
• HNSCC
• Melanoma
• Mesothelioma
• NSCLC
• Pancreas Adenocarcinoma
• Renal Cell Carcinoma
• Urinary Bladder Neoplasms
• Urothelial Carcinoma Bladder

Intervention

Drug:
• Milademetan
260 mg once daily orally on 3 consecutive day sets with a minimum of 14 days and a maximum of 21 days between the first day of each 3- day dosing set.
• Atezolizumab
1680mg administered every 4 weeks

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Rain Oncology Inc

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The number of participants with treatment related AEs meeting DLT-defined criteria assessed by CTCAE v5.0 when receiving milademetan in combination with atezolizumab in patients with advanced solid tumors with HZ CDKN2A loss and WT TP53		4 months
Primary	The appropriate dose of milademetan in combination with atezolizumab based on the number of participants with DLT-defined adverse events assessed by CTCAE v5.0 criteria		4 months
Primary	Treatment emergent AE of the identified RP2D of milademetan in combination with atezolizumab in patients with advanced solid tumors with HZ CDKN2A loss and WT TP53		24 months
Secondary	Objective response rate (ORR)	ORR, defined as the percentage of patients who achieve a confirmed CR or PR	24 months
Secondary	Duration of response (DOR)	DOR, defined as the time from the date of first response (CR or PR) to the date of radiologically demonstrated disease progression, or death due to any cause	24 months
Secondary	Disease control rate (DCR)	DCR, defined as the percentage of patients who achieve CR, PR, or SD for = 16 weeks	24 months
Secondary	Progression Free Survival (PFS)	PFS, defined as the time from the date of first dose to the earliest date of the first objective documentation of radiographic disease progression, or death due to any cause	24 months
Secondary	Growth Modulation Index (GMI)	GMI: The GMI will be determined using the ratio of time to progression (TTP) with nth line of therapy (TTPn; here defined milademetan plus atezolizumab) to the most recent prior line of therapy (TTPn-1)	24 months
Secondary	Pharmacokinetics Cmax	PK: maximum plasma concentration (Cmax) of milademetan	Initiation of study treatment through milademetan dose 13, an average of 3 months
Secondary	Pharmacokinetics AUC	PK: area under the plasma concentration-time curve (AUC)	Initiation of study treatment through milademetan dose 13, an average of 3 months
Secondary	Pharmacokinetics Tmax	PK: Time to reach maximum plasma concentration of milademetan	Initiation of study treatment through milademetan dose 13, an average of 3 months